Allogenic Adipose-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis

Knee Osteoarthritis Clinical Trial

Official title:

A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) Therapy for Knee Osteoarthritis.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05996224
• Other study ID #: CBM-MPC-007
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: October 2023
• Est. completion date: December 2027

Study information

• Verified date: August 2023
• Source: Cellular Biomedicine Group Ltd.
• Contact: Chunde Bao, M.D. & Ph.D.
• Phone: M.D. & Ph.D.
• Email: xck[@]renji.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy

Description:

A Multicenter, Randomized, Double-blind, Controlled Phase III Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) Therapy for Knee Osteoarthritis.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 488
• Est. completion date: December 2027
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subjects who understand and voluntarily sign the consent form before this study;

2. According to the diagnostic criteria (American Rheumatology Association, clinical + radiology criteria), patients with knee osteoarthritis are definitely diagnosed;

3. Age: 40-75, males and females;

4. The course of knee osteoarthritis was more than 6 months;

5. The subjects' WOMAC score was 24-72, and the WOMAC pain score was 7-17 (the WOMAC score at least 48 hours after discontinuation of all painkillers);

6. The Kellgren Lawrence grade (X-ray axial position of knee joint) of subjects was grade II / III;

7. Subjects are generally in good condition and can walk autonomously, except for those who use wheelchairs, walking aids or crutches.

Exclusion Criteria:

1. The subject may be allergic to the main cell preparation components (B vitamins, amino acids and so on).

2. The subject received systemic and / or local treatment with autologous and / or allogeneic mesenchymal progenitor cells.

3. The subject has a BMI of over 30.

4. Laboratory test (any item meets): neutrophil absolute number < 1.0 × 10^9 / L, platelet count < 50 × 10^9 / L, serum albumin < 30g / L, serum creatinine > upper limit of 1.2 times normal value range, total bilirubin?alanine aminotransferase?aspartate aminotransferase > upper limit of 2 times of normal value range.

5. The subject has diseases or symptoms may affect VAS, WOMAC and so on.

6. The subject has serious and poorly controlled concomitant diseases, such as (but not limited to) nervous system, cardiovascular, liver, kidney, gastrointestinal and endocrine diseases, which may prevent the subjects from participating in the study according to the judgment of the researchers.

7. The subject has an history malignant tumour.

8. The subject has connective tissue disease or rheumatoid arthritis?chondropathy?Chondrocalcinosis articularis? Hemochromatosis?inflammatory arthropathy?avascular necrosis of femoral head?Paget's disease?hemophilic arthropathy?infectional arthritis?Charcot' s disease?villonodular synovitis or synovial chondromatosis.

9. The subject has severe generalized infectious diseases or local knee infection (including skin and intra-articular infection) in the 3 months prior to this trial.

10. According to the researchers, the subject has disease of lower limbs which may be interfered knee evaluation, for example fibromyalgia, osphyalgia, lumbar disc protrusion and so on.

11. The subject had any other coagulation dysfunction caused by acute or chronic diseases, according to the judgment of the researchers, this coagulation dysfunction may endanger the safety of patients and / or affect the judgment of knee joint evaluation indicators.

12. The subject has received arthroscopic surgery or other open surgery related to knee joint operation in the 6 months prior to this trial.

13. The subject has received other intra-articular injections, including but not limited to hyaluronic acid, hormone, PRP, BMP (bone morphogenetic protein) , hypertonic glucose and so on for KOA in the 3 months preceding the trial.

14. The subject has received aminoglucose or chondroitin sulfate within 1 month before the treatment.

15. The subject has used dexamethasone, prednisone, hydrocortisone and other hormones orally / intravenously within 1 month before the treatment.

16. The subject has attenuated or live attenuated vaccine injection with 1 month before the treatment.

17. The subject has undergone knee prosthesis or a plan of knee prosthesis within the trial.

18. The subject has contraindication of MRI, included but not only: the subject installed heart pacemaker, defibrillator, heart bracket, heart valve prosthesis, metal clip after aneurysm surgery, drug infusion device implanted in vivo, any electronic device implanted in the body (nerve stimulator, bone growth stimulator) endovascular coil, strainer, ECG monitor, metal suture, shrapnel or sand of body, plate fixation and steel nail after fracture surgery, artificial cochlea, middle ear shift plant, metallic intraocular foreign body etc; the subject is a claustrophobia, critical ill patient and so on.

19. The subject tests positive for: HIV, HBV, HCV and treponema pallidum.

20. The subject has history of alcoholism, drug abuse, or mental illness in the 3 years prior to this trial.

21. The subject has participated in any other clinical trial in the 3 months prior to this trial.

22. The subject (including male subjects) has fertility, sperm donation or egg donation plans during the trial period; the female subject is pregnant, lactating or having a positive pregnancy test.

23. The subject is legally disabled by reference to the law of the people's Republic of China on the protection of disabled persons (April 2008).

24. The subject has any other unsuitable condition (such as factors reducing the follow-up compliance) to be determined by the investigator.

25. The Kellgren Lawrence grade (X-ray axial position of knee joint) of any knee joint of the subjects was grade IV.

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Biological:
• Mesenchymal progenitor cells
Allogenic Adipose tissue-derived mesenchymal progenitor cells administrated for intra- articular use

Drug:
• Sodium Hyaluronate Injection
Sodium Hyaluronate administrated for intra-articular use

Locations

Country	Name	City	State
China	China-Japan Friendship Hospital	Beijing
China	The Second Affiliated hospital of Zhejiang University School of Medicine	Hangzhou
China	Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China	Shanghai	Shanghai
China	Huashan Hospital Affiliated to Fudan University	Shanghai
China	Shanghai General Hospital	Shanghai
China	Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Cellular Biomedicine Group Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Inflammatory biomarkers detection	Prostaglandin E2 in serum will be tested at Day 0 and week 4?12?24?36?48?96	Day 0 and week 4?12?24?36?48?96
Primary	WOMAC score	The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points;96 points mean a worse outcome,will be tested at 24 weeks after the first injection	24 weeks
Secondary	MRI quantitative analysis of articular cartilage	Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 48 weeks after the first injection	48 weeks
Secondary	WOMAC Score	The Western Ontario and McMaster Universities Osteoarthritis Index;0-96 points;96 points mean a worse outcome, will be tested at 4?12?24?36?48?60?72?84 and 96 weeks after the first injection	4?12?24?36?48?60?72?84?96 weeks
Secondary	VAS Score	Visual Analogue Scale/Score;0-10 points;10 points mean the worse outcome,will be tested at 4?12?24?36?48?60?72?84 and 96 weeks after the first injection	4?12?24?36?48?60?72?84?96 weeks
Secondary	SF-36	The Medical Outcomes Study 36-Item Short-Form Health Survey;0-100 points;100 points mean a better outcome, will be tested at 4?12?24?36?48?60?72?84 and 96 weeks after the first injection	4?12?24?36?48?60?72?84?96 weeks
Secondary	MRI quantitative analysis of articular cartilage	Magnetic Resonance Imaging analysis of articular cartilage, will be tested at 24 and 96 weeks after the first injection	24 weeks and 96 weeks
Secondary	Whole-Organ Magnetic Resonance Imaging Score	Whole-Organ Magnetic Resonance Imaging Score(WORMS) of the knee; 0-332points; 332 points means the worst outcome; will be assessed at 24?48 and 96 weeks	24?48 and 96 weeks
Secondary	mJSW	Minimum joint space width (mJSW) of the knee, will be measured at baseline and 96 weeks	96 weeks
Secondary	Adverse Events and Serious Adverse Events	AE and SAE, will be assessed within the 96 week time span	Day 0 to 96 weeks
Secondary	Physical examination	Height and weight will be tested and combined to report BMI in kg/m^2at Day 0 and week 1?2?3?4?12?24?36?48?60?72?84?96	Day 0?week 1?2?3?4?12?24?36?48?60?72?84?96